Recent articles
2 Top Biotech Stocks to Buy in December
These companies are carving their own paths in cellular medicine. One just posted promising clinical results, while the other aims to do so this month.
This Small-Cap Biotech Rose as Much as 98.3% Today
Forty Seven jumped on promising data for its lead drug candidate.
2 Top Value Stocks to Buy in December
These industry leaders aren't getting much love from Mr. Market. That just sets the stage for an inevitable rebound, right?
2 Top Growth Stocks to Buy in December
These two companies are piggybacking on the growth of solar energy and distributed energy generation.
John Kerry's Climate Coalition Highlights the Importance of Natural Gas
Global emissions reduction efforts are likely to be much more successful if one controversial energy source is included -- if only temporarily.
Celgene Gave This Tech Back to Editas Medicine, but It Could Prove Valuable
An amended collaboration agreement limited the types of immune cells that will be pursued by the duo, but that could create more value for Editas Medicine in the long run.
Here's Why Sage Therapeutics Lost as Much as 62.1% Today
An important clinical trial turned in underwhelming results.
Here's Why Arrowhead Pharmaceuticals Is Tumbling Today
Now that the initial excitement has worn off, investors are correctly responding to the news of a public stock offering.
Here's Why BioMarin Pharmaceutical Leapt 10.2% in November
The business reported a handful of positive developments.
Here's Why Vertex Pharmaceuticals Rose 13.4% in November
The rare-disease specialist is putting together a respectable end-of-year run.
Here's Why Editas Medicine Jumped 45.3% in November
The gene editing pioneer got a boost from a collaborator and a competitor.
Here's Why Guardant Health Gained 11.8% in November
The diagnostic company reported third-quarter 2019 operating results.
Here's Why Arrowhead Pharmaceuticals Is Soaring Today
Counterintuitively, investors are bidding up the share price after the company announced a public stock offering.
Here's Why Alnylam Pharmaceuticals Rose 35.1% in November
The RNAi pioneer earned a surprise drug approval. It could have far-reaching implications for the company's future.
Here's Why CRISPR Therapeutics Jumped 42.2% in November
The gene-editing pioneer reported promising data, albeit from two patients.
Is Clovis Oncology Really a Buyout Candidate?
The stock price is soaring. Are investors getting ahead of themselves by speculating on a potential acquisition?
Does a Surprise Approval Make Alnylam Pharmaceuticals a Buy?
Investors were caught off guard when the genetic medicines company earned marketing approval for its second RNAi drug product sooner than expected.
1 Reason Investors Shouldn't Panic Over the Latest U.N. Climate Report
The latest progress report on global emissions reduction efforts showed there's a lot room for improvement, but the United States is doing its part.
Here's Why Lexicon Pharmaceuticals Is Tumbling Today
The FDA rebuffed the company's appeal for a failed new drug application. What happens now?
Is Lexicon Pharmaceuticals a Buy?
Despite doubts over its lead drug candidate and the loss of a major partner, the company is forging ahead.